Asenapine + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
May 25, 2010 → Apr 22, 2015
NCT ID
NCT01142596About Asenapine + Placebo
Asenapine + Placebo is a phase 3 stage product being developed by Organon for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01142596. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01142596 | Phase 3 | Completed |
| NCT00145509 | Phase 3 | Completed |
| NCT00145470 | Phase 3 | Completed |
Competing Products
20 competing products in Schizophrenia